Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micromet Inc (MITI) -- Ignore unavailable to you. Want to Upgrade?

To: dr.praveen who wrote (34)	6/15/2006 12:13:10 PM
From: dr.praveen	Read Replies (1) \| Respond to of 196

Study Supports Potential of Micromet's Human Antibody MT203 As Novel Anti-Inflammatory Treatment Thursday June 15, 2:57 am ET MÃœNCHEN, GERMANY--(MARKET WIRE)--Jun 15, 2006 -- Carlsbad, CA - June 15, 2006 - Micromet, Inc. (NasdaqNM:MITI - News), a transatlantic biopharmaceutical company focused on the development of antibody-based drugs, reports results of a scientific study1 published in Molecular Immunology. The study describes one of the first human, high-affinity IgG1 antibodies potently neutralizing human GM-CSF. The compound, designated MT203, was generated by Micromet using phage display-guided selection and is currently in preclinical development as a novel treatment for inflammatory and autoimmune diseases including but not limited to rheumatoid arthritis (RA), asthma, chronic obstructive pulmonary disease (COPD), multiple sclerosis (MS) and psoriasis. ADVERTISEMENT Results from in-vitro studies demonstrate that MT203 binds human GM-CSF with low picomolar affinity and potently prevents GM-CSF-induced proliferation as well as production of the chemokine IL-8. Moreover, the human antibody was observed to significantly reduce both the activation and survival of human eosinophils, which are are involved in the development of a number of inflammatory lung diseases. MT203 retained full neutralizing activity after 5 days in human serum at 37°C. "We have designed MT203 to meet the highest industry standards for a novel cytokine-neutralizing antibody in terms of validated antibody format, highest potency and stability, lowest possible immunogenicity, and crossreactivity with non-human primates as is required for safety studies," Patrick Baeuerle, Chief Scientific Officer of Micromet, commented. "By neutralizing GM-CSF, we believe we have tapped a novel pharmaceutical target for the potential treatment of patients with inflammatory diseases." GM-CSF was only recently recognized as a key pro-inflammatory cytokine responsible for the proliferation, activation, and survival of a host of immune cells, which play pivotal roles in the development and progression of inflammatory diseases. A significant benefit of neutralizing GM-CSF has been shown in animal models for RA, MS, COPD, asthma and psoriasis.